Literature DB >> 11895771

Early hematopoietic reconstitution after clinical stem cell transplantation: evidence for stochastic stem cell behavior and limited acceleration in telomere loss.

Ian Thornley1, Robert Sutherland, Robert Wynn, Rakash Nayar, Lillian Sung, George Corpus, Thomas Kiss, Jeff Lipton, John Doyle, Fred Saunders, Suzanne Kamel-Reid, Melvin Freedman, Hans Messner.   

Abstract

Our inability to purify hematopoietic stem cells (HSCs) precludes direct study of many aspects of their behavior in the clinical hematopoietic stem cell transplantation (HSCT) setting. We indirectly assessed stem/progenitor cell behavior in the first year after HSCT by examining changes in neutrophil telomere length, X-inactivation ratios, and cycling of marrow progenitors in 25 fully engrafted allogeneic HSCT recipients. Donors were sampled once and recipients at engraftment and 2 to 6 months and 12 months after HSCT. Telomere length was measured by an in-gel hybridization technique, X-inactivation ratios were measured by the human androgen receptor assay, and cell cycle status was determined by flow cytometric analysis of pyronin Y- and Hoechst 33342-stained CD34(+)CD90(+) and CD34(+)CD90(-) marrow cells. Compared with their donors, recipients' telomeres were shortened at engraftment (-424 base pairs [bp]; P <.0001), 6 months (-495 bp; P =.0001) after HSCT, and 12 months after HSCT (-565 bp; P <.0001). There was no consistent pattern of change in telomere length from 1 to 12 months after HSCT; marked, seemingly random, fluctuations were common. In 11 of 11 informative recipients, donor X-inactivation ratios were faithfully reproduced and maintained. The proportion of CD34(+)CD90(+) progenitors in S/G(2)/M was 4.3% in donors, 15.7% at 2 to 6 months (P <.0001) after HSCT, and 11.5% at 12 months after HSCT (P <.0001, versus donors; P =.04, versus 2-6 months). Cycling of CD34(+) CD90(-) progenitors was largely unchanged. We infer that (1) HSCT-induced accelerated telomere loss is temporary and unlikely to promote graft failure or clonal hematopoietic disorders and (2) the striking fluctuations in telomere length and variation in pattern of telomere loss reflect stochastic determination of HSC fate after HSCT.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11895771     DOI: 10.1182/blood.v99.7.2387

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  The hematopoietic stem compartment consists of a limited number of discrete stem cell subsets.

Authors:  Hans B Sieburg; Rebecca H Cho; Brad Dykstra; Naoyuki Uchida; Connie J Eaves; Christa E Muller-Sieburg
Journal:  Blood       Date:  2005-11-15       Impact factor: 22.113

2.  Dynamics of epigenetic age following hematopoietic stem cell transplantation.

Authors:  Friedrich Stölzel; Mario Brosch; Steve Horvath; Michael Kramer; Christian Thiede; Malte von Bonin; Ole Ammerpohl; Moritz Middeke; Johannes Schetelig; Gerhard Ehninger; Jochen Hampe; Martin Bornhäuser
Journal:  Haematologica       Date:  2017-05-26       Impact factor: 9.941

3.  Age-adjusted recipient pretransplantation telomere length and treatment-related mortality after hematopoietic stem cell transplantation.

Authors:  Régis Peffault de Latour; Rodrigo T Calado; Marc Busson; Jeffrey Abrams; Nadir Adoui; Marie Robin; Jérôme Larghero; Nathalie Dhedin; Alienor Xhaard; Emmanuel Clave; Dominique Charron; Antoine Toubert; Pascale Loiseau; Gérard Socié; Neal S Young
Journal:  Blood       Date:  2012-09-04       Impact factor: 22.113

Review 4.  Telomere biology in hematopoiesis and stem cell transplantation.

Authors:  Shahinaz M Gadalla; Sharon A Savage
Journal:  Blood Rev       Date:  2011-07-20       Impact factor: 8.250

5.  Multi-color immune-phenotyping of CD34 subsets reveals unexpected differences between various stem cell sources.

Authors:  J Dmytrus; S Matthes-Martin; H Pichler; N Worel; R Geyeregger; N Frank; C Frech; G Fritsch
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483

6.  Epigenetic Aging and Hematopoietic Cell Transplantation in Patients With Severe Aplastic Anemia.

Authors:  Rotana Alsaggaf; Shilpa Katta; Tao Wang; Belynda D Hicks; Bin Zhu; Stephen R Spellman; Stephanie J Lee; Steve Horvath; Shahinaz M Gadalla
Journal:  Transplant Cell Ther       Date:  2021-01-16

Review 7.  Immune Reconstitution in the Aging Host: Opportunities for Mechanism-Based Therapy in Allogeneic Hematopoietic Cell Transplantation.

Authors:  Richard J Lin; Harold K Elias; Marcel R M van den Brink
Journal:  Front Immunol       Date:  2021-04-19       Impact factor: 7.561

8.  High incidence of microsatellite instability and loss of heterozygosity in three loci in breast cancer patients receiving chemotherapy: a prospective study.

Authors:  Nasir Kamat; Mohammed A Khidhir; Mohammed Jaloudi; Sabir Hussain; Mouied M Alashari; Khaled H Al Qawasmeh; Ulf Rannug
Journal:  BMC Cancer       Date:  2012-08-28       Impact factor: 4.430

9.  Successful elimination of non-neural cells and unachievable elimination of glial cells by means of commonly used cell culture manipulations during differentiation of GFAP and SOX2 positive neural progenitors (NHA) to neuronal cells.

Authors:  Monika Witusik; Sylwester Piaskowski; Krystyna Hulas-Bigoszewska; Magdalena Zakrzewska; Sylwia M Gresner; S Ausim Azizi; Barbara Krynska; Pawel P Liberski; Piotr Rieske
Journal:  BMC Biotechnol       Date:  2008-07-19       Impact factor: 2.563

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.